Document is current
Any future updates will be listed below
-
Authors
Zeng, Yi
Arisa, Oluwatobi
Corvalan, Natalia
Bateman, Francis
Schmidt, Keith
Peer, Cody
Figg, William D.
-
Funding
Funding for this research was provided by:
National Cancer Institute
- License Information
-
More Information
Article History
Received: 12 May 2025
Accepted: 10 September 2025
First Online: 19 January 2026
Declarations
:
: WDF receives research funding from Propella Therapeutics Inc, and has active licenses with Aevis Bio and Novartis. All remaining authors declare no competing interests.
: The analysis is comparing pharmacokinetic software programs using simulated data. Thus, there are no consents, IRB approval, or other patient protection concerns. Clinical trial number: not applicable.
: The views, information, or content, and conclusions presented do not necessarily represent the official position or policy of, nor should any official endorsement be inferred on the part of the Clinical Center or the National Cancer Institute, the National Institutes of Health, or the Department of Health and Human Services.
